Any current/future new fundraising through debt or equity?

No new external financing or incremental capex is planned for the next two years; the company plans to utilize available cash of around INR180 crores to complete ongoing capex. Prefential allotment proceeds (preferential shares and warrants) worth INR39 million are expected to come in over the next 12 to 18 months, which will be used to repay debt, especially long-term debt. The company aims to use operating cash flow and these proceeds to reduce net debt and manage the balance sheet efficiently. There is no indication of fresh fundraising via new debt or equity beyond the already planned pref

Any current/future capex/capital investment/strategic investment?

The company has a total announced capex of INR 670 crores, out of which INR 482 crores have been utilized as of March 31, 2024. The balance capex (around INR 180 crores) will be incurred in the coming quarters, with plants expected to be commercialized by the first half of FY2025. There is no plan for any new or incremental capex beyond the existing INR 670 crores plan. Future capex guidance for FY’25 is around INR 180 crores (balance from existing plan) plus maintenance capex. For FY’26, the capex will primarily be maintenance capex with no new major capital investments planned. The existing

Future growth expectations in sales/revenue/volumes?

CY'25 is expected to show far better growth than CY'24; CY'24 is better than CY'23. First two quarters of FY’25 may be tepid, with stronger growth anticipated in the third and fourth quarters. Agrochem segment expected to face headwinds initially but will contribute to growth along with polymer and pharma segments. Volumes for CY'25 are expected to be higher than CY'23 on existing orders, indicating a catch-up. Peak revenue potential from current plants (including new fluorination block) is around INR 3,000 crores. Revenue from LOIs is scaling: ~INR 200 crores in FY’24; expected INR 350+ crore

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 expected to be a year of growth, driven primarily by the Polymer and Pharmaceutical segments. Pharma segment’s revenue contribution increased from 4% in FY23 to 9% in FY24; expected to reach double digits in FY25. Polymer segment currently in single digits but anticipated to reach double digits in FY25. Margins expected to remain healthy around 26%+ EBITDA margin on a stand-alone basis. Revenue growth may be cautious in H1 FY25 with stronger growth in H2 FY25. Total peak revenue potential is around INR 3,000 crores considering full utilization of current and upcoming capacity (including t

Current/ Expected Orderbook/ Pending Orders?

The current order book (LOIs) is just under INR 9,000 crores. Average revenue run rate from this order book, considering an average contract duration of 5-7 years, is estimated around INR 1,300 to 1,400 crores annually. LOIs take approximately 18-24 months to commercialize after signing. Post-commercialization, full volume ramp-up takes an additional 18-24 months. For FY24, revenue from LOIs was slightly under INR 200 crores. FY25 LOI revenue is expected around INR 350 crores, with potential for INR 400 crores. Contracts include long-term take-or-pay clauses with minimum offtake guarantees. Fl

Anupam Rasayan India LtdQ4 FY24Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,182P/E: 77.0Market Cap: ₹13.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

CY'25 is expected to show far better growth than CY'24; CY'24 is better than CY'23.
First two quarters of FY’25 may be tepid, with stronger growth anticipated in the third and fourth quarters.
Agrochem segment expected to face headwinds initially but will contribute to growth along with polymer and pharma segments.
Volumes for CY'25 are expected to be higher than CY'23 on existing orders, indicating a catch-up.
Peak revenue potential from current plants (including new fluorination block) is around INR 3,000 crores.
Revenue from LOIs is scaling: ~INR 200 crores in FY’24; expected INR 350+ crores in FY’25.
Order book of about INR 9,000 crores spread over 5-7 years implies a steady addition of roughly INR 1,300-1,400 crores yearly.
Capacity utilization currently around 70-75%; revenue potential roughly INR 1,600-1,700 crores without new capex.

Margin guidance

Category 3

FY25 expected to be a year of growth, driven primarily by the Polymer and Pharmaceutical segments.
Pharma segment’s revenue contribution increased from 4% in FY23 to 9% in FY24; expected to reach double digits in FY25.
Polymer segment currently in single digits but anticipated to reach double digits in FY25.
Margins expected to remain healthy around 26%+ EBITDA margin on a stand-alone basis.
Revenue growth may be cautious in H1 FY25 with stronger growth in H2 FY25.
Total peak revenue potential is around INR 3,000 crores considering full utilization of current and upcoming capacity (including the fluorination block).
Incremental capex limited (~INR180 crores for FY25), mainly for completion of existing plans; FY26 capex expected to be maintenance only.
Working capital normalization expected over next 18-24 months, improving return ratios.

See what Anupam Rasayan India Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No new external financing or incremental capex is planned for the next two years; the company plans to utilize available cash of around INR180 crores to complete ongoing capex.
Prefential allotment proceeds (preferential shares and warrants) worth INR39 million are expected to come in over the next 12 to 18 months, which will be used to repay debt, especially long-term debt.
The company aims to use operating cash flow and these proceeds to reduce net debt and manage the balance sheet efficiently.
There is no indication of fresh fundraising via new debt or equity beyond the already planned preferential allotment and utilization of existing cash reserves.
Management remains cautious and prefers to see business performance for a quarter or two before providing further guidance on financial moves.

Order book

Yes

The current order book (LOIs) is just under INR 9,000 crores.
Average revenue run rate from this order book, considering an average contract duration of 5-7 years, is estimated around INR 1,300 to 1,400 crores annually.
LOIs take approximately 18-24 months to commercialize after signing.
Post-commercialization, full volume ramp-up takes an additional 18-24 months.
For FY24, revenue from LOIs was slightly under INR 200 crores.
FY25 LOI revenue is expected around INR 350 crores, with potential for INR 400 crores.
Contracts include long-term take-or-pay clauses with minimum offtake guarantees.
Flexibility exists in contracts for compensation, price adjustments, or product mix changes in case of delays.
Business expects growth in LOI commercializations and volume ramp-up over the next 2-3 years.

See what Anupam Rasayan India Ltd management said on order book — free account, 30 seconds.

Capex plans

The company has a total announced capex of INR 670 crores, out of which INR 482 crores have been utilized as of March 31, 2024.
The balance capex (around INR 180 crores) will be incurred in the coming quarters, with plants expected to be commercialized by the first half of FY2025.
There is no plan for any new or incremental capex beyond the existing INR 670 crores plan.
Future capex guidance for FY’25 is around INR 180 crores (balance from existing plan) plus maintenance capex.
For FY’26, the capex will primarily be maintenance capex with no new major capital investments planned.
The existing capex is expected to support a peak revenue potential of around INR 3,000 crores.
No external financing is required for this capex as the cash reserves suffice.

Track Anupam Rasayan India Ltd — get its next earnings analysis in your feed

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisAnupam Rasayan India Ltd

Rev 3Mar 3

See where Anupam Rasayan India Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Anupam Rasayan India Ltd rank in Chemicals & Petrochemicals?

Compare Anupam Rasayan India Ltd against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Anupam Rasayan India Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Alufluoride Ltd (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Anupam Rasayan India Ltd Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Anupam Rasayan India Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Anupam Rasayan India Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season